AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00022113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00022113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00786409 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Gardasil
Description: 0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
Study NCT03893630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid 81 mg
Description: Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Study NCT00212615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin (Eloxatin)
Study NCT03893630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic Acid 162 mg
Description: Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Study NCT01400516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TNF antagonist
Description: TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
Study NCT01400516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNF antagonist
Description: TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
Study NCT00564655 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine with epinephrine (mid and upper abdomen)
Description: Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
Study NCT00564655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bupivacaine with epinephrine (transversus abdominis plane)
Description: 0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
Study NCT03226340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-amlodipine 2.5mg + Chlorthalidone 25mg
Description: patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
Study NCT03226340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 2.5mg + Telmisartan 40mg
Description: patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
Study NCT02023450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir and ritonavir
Description: micro and low dose
Study NCT02023450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir and ritonavir
Description: standard dose
Study NCT04400903 — intervention group
Intervention type: DEVICE
Intervention: Activity Monitor
Description: Undergo HRV monitoring via WHOOP device
Study NCT04400903 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04400903 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01116258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5847
Description: oral suspension, 15 days
Study NCT01116258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral suspension, 15 days
Study NCT01220258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin ophthalmic solution, 1%
Description: 1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
Study NCT02159755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02159755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02159755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study NCT02159755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT03404622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IUCD
Description: IUCD will be inserted in 100 women post placental removal and will be inserted in anther 100 women after six weeks post cesarean delivery
Study NCT04345172 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sub-Tenon's block with a lacrimal dilator group or a Wescott scissors
Description: Local anaesthetic eye drops were installed into the conjunctiva, followed by iodine 5% aqueous drops to the conjunctival sac for 3 minutes.19 An eye lid speculum was inserted.~In group LD, the conjunctiva and Tenon's capsule were lifted together tightly with a blunt forceps like a tent in the inferonasal quadrant and a punctal dilatator (Castroviejo Lacrimal Dilatator, Katena Products, Inc, Denville, NJ, USA) was placed tangential to the globe creating a round and small hole at 5 mm posterior to limbus (Fig.1). The block was performed using smooth rounded tip, 19 G, 1 inch sub-Tenon's cannula (Visitec, Beaver-Visitec International Ltd, Warwickshire, UK).~In Group WS, after lifting the conjunctiva and Tenon's capsule together with a blunt forceps, incision was performed with a blunt tip Westcott scissors in the inferonasal conjunctival at 5 mm posterior to limbus to expose sub-Tenon's space.
Study NCT03101137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal block with dexmedetomedine
Description: After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
Study NCT03101137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal dexamethasone
Description: After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
Study NCT01282294 — intervention group
Intervention type: DEVICE
Intervention: ETN PROtect
Description: Expert Tibial Nail PROtect with Gentamicin coating
Study NCT04070937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: audiometry
Description: tonal liminar audiometric thresholds
Study NCT04070937 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT and MR imaging of temporal bone
Description: Ct and MR imaging of temporal bone
Study NCT04070937 — intervention group
Intervention type: GENETIC
Intervention: p.P51S mutation
Description: analysis of presence of p.P51S mutation in COCH
Study NCT01563016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: glucose drink
Description: participants will receive a drink rich in glucose
Study NCT01563016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: glucose drink
Description: participants will receive a drink rich in glucose
Study NCT01655147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
Study NCT01655147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
Study NCT03168360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive rehabilitation
Description: Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
Study NCT03168360 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Description: Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
Study NCT00212615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine (Xeloda)
Study NCT01232153 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non invasive ventilation
Description: Non invasive ventilation
Study NCT02623504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: 200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
Study NCT02623504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage to match active treatment by mouth twice daily in the morning and in the evening.
Study NCT03101137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control (bupivacaine)
Description: After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
Study NCT00560950 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal 23v polysaccharide vaccine
Description: Duration of Treatment: Single vaccination on Day 1
Study NCT00056446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vatalanib
Study NCT00056446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vatalanib
Study NCT02905006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Subjects will be randomized to receive a combination of injections of Bimekizumab.
Study NCT02905006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Study NCT02905006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
Study NCT00877370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
Study NCT00867555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation
Description: green tea extract TEAVIGO, high in EGCG
Study NCT00867555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation
Description: green tea extract TEAVIGO, high in EGCG
Study NCT03331822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright Light
Description: high illuminance white lights positioned at each nursing station throughout the hallway to generate a uniform exposure of approximately 1,000-3,000 lux. To achieve this illuminance, a Day\*Light Classic Light will be positioned at each nursing station in the ICU hallway.
Study NCT01750359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: 500 mg/day for 6 week
Study NCT01750359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: curcumin
Description: 500 mg/day for 6 week
Study NCT02396394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-Step Adherence Feedback
Description: Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is \<95%.
Study NCT01883752 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goal-directed Therapy group
Description: Fluid administration is based on the respiratory variation in the pulse oximeter waveform
Study NCT02582047 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination with PPV23
Description: GCflu and Pneumovax-23
Study NCT02582047 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccination with PCV13
Description: GCflu and Prevenar-13
Study NCT01751139 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample collection
Description: Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
Study NCT01751139 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Data collection
Description: Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
Study NCT00490776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat, 20 mg, hard gelatin capsules, orally, thrice weekly.
Study NCT03199391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioWick SureLock Implant
Description: The BioWick SureLock implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick SureLock is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
Study NCT02297555 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOBARRIER®
Description: This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
Study NCT00086099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubincin and Amufostine (Ethyol)
Description: Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
Study NCT00086099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubincin
Description: Idarubincin (12mg/m2) and ara-C(N-18)
Study NCT03591172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Using propolis as a final irrigation in revascularization
Study NCT03591172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nano-propolis
Description: Using Nano-propolis as a final irrigation in revasculariztion
Study NCT03591172 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: Using saline as a final irrigation in revasculariztion
Study NCT02785419 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm Training with Action Selection
Description: Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
Study NCT02880527 — intervention group
Intervention type: OTHER
Intervention: Patients with polymyositis / dermatomyositis
Description: recruitment of patients with polymyositis / dermatomyositis using :~1. medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;~2. general practitioners~3. the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )~5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association
Study NCT03924921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autogenic training
Description: autogenic training
Study NCT01566578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human recombinant epidermal growth factor
Description: topical
Study NCT01566578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Dermal cream without EGF
Study NCT02506660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT02506660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study NCT02506660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Description: Dexamethasone in nerve block
Study NCT02506660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexamethasone
Study NCT02506660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous saline
Study NCT02506660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perineural saline
Description: Saline in nerve block
Study NCT03103035 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blog
Description: Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
Study NCT02187315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chrono-chemotherapy pump:Melodie
Study NCT02187315 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Routine intravenous drip
Study NCT02187315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Study NCT02187315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: induction chemotherapy
Study NCT02187315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin chrono-chemotherapy
Study NCT02187315 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study NCT02187315 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: intensity-modulated radiation therapy
Study NCT02187315 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin routine-chemotherapy
Study NCT03551756 — intervention group
Intervention type: OTHER
Intervention: Biomarker Assessment
Description: Exploratory Biomarker Analysis for cardiac patients versus healthy adults